LYRA Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -23936% compared to Lyra Therapeutics, Inc.'s net margin of 12.65%. Lyra Therapeutics, Inc.'s return on equity of -493.53% beat Electromed, Inc.'s return on equity of 18.89%.

Lyra Therapeutics, Inc. has a consensus price target of $11.50, signalling upside risk potential of 205.28%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25%. Given that Lyra Therapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Lyra Therapeutics, Inc. is more attractive than Electromed, Inc..

Lyra Therapeutics, Inc. has a beta of 0.011, which suggesting that the stock is 98.867% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.

Lyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyra Therapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Lyra Therapeutics, Inc. quarterly revenues are $25K, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Lyra Therapeutics, Inc.'s net income of -$6M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Lyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyra Therapeutics, Inc. is 210.94x versus 3.84x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of -23936% compared to Lyra Therapeutics, Inc.'s net margin of 6.19%. Lyra Therapeutics, Inc.'s return on equity of -493.53% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Lyra Therapeutics, Inc. has a consensus price target of $11.50, signalling upside risk potential of 205.28%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 63.78%. Given that Lyra Therapeutics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Lyra Therapeutics, Inc. is more attractive than InfuSystem Holdings, Inc..

Lyra Therapeutics, Inc. has a beta of 0.011, which suggesting that the stock is 98.867% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Lyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyra Therapeutics, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Lyra Therapeutics, Inc. quarterly revenues are $25K, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Lyra Therapeutics, Inc.'s net income of -$6M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Lyra Therapeutics, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyra Therapeutics, Inc. is 210.94x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona, Inc. has a net margin of -23936% compared to Lyra Therapeutics, Inc.'s net margin of -47.35%. Lyra Therapeutics, Inc.'s return on equity of -493.53% beat Dentsply Sirona, Inc.'s return on equity of -44.58%.

Lyra Therapeutics, Inc. has a consensus price target of $11.50, signalling upside risk potential of 205.28%. On the other hand Dentsply Sirona, Inc. has an analysts' consensus of $12.83 which suggests that it could grow by 0.42%. Given that Lyra Therapeutics, Inc. has higher upside potential than Dentsply Sirona, Inc., analysts believe Lyra Therapeutics, Inc. is more attractive than Dentsply Sirona, Inc..

Lyra Therapeutics, Inc. has a beta of 0.011, which suggesting that the stock is 98.867% less volatile than S&P 500. In comparison Dentsply Sirona, Inc. has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.3%.

Lyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona, Inc. offers a yield of 5.01% to investors and pays a quarterly dividend of $0.16 per share. Lyra Therapeutics, Inc. pays -- of its earnings as a dividend. Dentsply Sirona, Inc. pays out 13.85% of its earnings as a dividend. Dentsply Sirona, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Lyra Therapeutics, Inc. quarterly revenues are $25K, which are smaller than Dentsply Sirona, Inc. quarterly revenues of $904M. Lyra Therapeutics, Inc.'s net income of -$6M is higher than Dentsply Sirona, Inc.'s net income of -$428M. Notably, Lyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Dentsply Sirona, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyra Therapeutics, Inc. is 210.94x versus 0.70x for Dentsply Sirona, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -23936% compared to Lyra Therapeutics, Inc.'s net margin of 3.93%. Lyra Therapeutics, Inc.'s return on equity of -493.53% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Lyra Therapeutics, Inc. has a consensus price target of $11.50, signalling upside risk potential of 205.28%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 119.94%. Given that Lyra Therapeutics, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Lyra Therapeutics, Inc. is more attractive than Xtant Medical Holdings, Inc..

Lyra Therapeutics, Inc. has a beta of 0.011, which suggesting that the stock is 98.867% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Lyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyra Therapeutics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Lyra Therapeutics, Inc. quarterly revenues are $25K, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Lyra Therapeutics, Inc.'s net income of -$6M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Lyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 66.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyra Therapeutics, Inc. is 210.94x versus 0.74x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.